A5015379222- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Renal and Vascular Pathologies
- PARP inhibition in cancer therapy
- Cancer Immunotherapy and Biomarkers
- Renal Transplantation Outcomes and Treatments
- Chronic Lymphocytic Leukemia Research
- Gastric Cancer Management and Outcomes
- Cancer-related gene regulation
- Central Venous Catheters and Hemodialysis
- Metastasis and carcinoma case studies
- Organ Donation and Transplantation
- Cancer-related Molecular Pathways
- Vascular Procedures and Complications
Hospital de Cruces
2025
Ludwig-Maximilians-Universität München
2024
Memorial Sloan Kettering Cancer Center
2024
Harbin Medical University
2024
National Hospital Organization Kyushu Cancer Center
2024
Institut Jules Bordet
2024
Université de Versailles Saint-Quentin-en-Yvelines
2024
Université Paris-Saclay
2024
Cornell University
2024
Research Institute Hospital 12 de Octubre
2023
BackgroundImlunestrant is a next-generation, brain-penetrant, oral selective estrogen-receptor (ER) degrader that delivers continuous ER inhibition, even in cancers with mutations the gene encoding ERα (ESR1).MethodsIn phase 3, open-label trial, we enrolled patients ER-positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer recurred or progressed during after aromatase inhibitor therapy, administered alone cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor....
Abstract Purpose: To evaluate a triplet regimen combining immune checkpoint blockade, AKT pathway inhibition, and (nab-) paclitaxel as first-line therapy for locally advanced/metastatic triple-negative breast cancer (mTNBC). Patients Methods: The single-arm CO40151 phase Ib study (NCT03800836), the signal-seeking cohort of IPATunity130 (NCT03337724), randomized III IPATunity170 trial (NCT04177108) enrolled patients with previously untreated mTNBC. Triplet comprised intravenous atezolizumab...
<div>AbstractPurpose:<p>To evaluate a triplet regimen combining immune checkpoint blockade, AKT pathway inhibition, and (nab-) paclitaxel as first-line therapy for locally advanced/metastatic triple-negative breast cancer (mTNBC).</p>Patients Methods:<p>The single-arm CO40151 phase Ib study (NCT03800836), the signal-seeking cohort of IPATunity130 (NCT03337724), randomized III IPATunity170 trial (NCT04177108) enrolled patients with previously untreated mTNBC. Triplet...
<div>AbstractPurpose:<p>To evaluate a triplet regimen combining immune checkpoint blockade, AKT pathway inhibition, and (nab-) paclitaxel as first-line therapy for locally advanced/metastatic triple-negative breast cancer (mTNBC).</p>Patients Methods:<p>The single-arm CO40151 phase Ib study (NCT03800836), the signal-seeking cohort of IPATunity130 (NCT03337724), randomized III IPATunity170 trial (NCT04177108) enrolled patients with previously untreated mTNBC. Triplet...
Aims Different methods in colorectal ESD (endoscopic submucosal dissection) are known: conventional (CM), tunnelled (TD), flap (FM), pocket (PCM), traction (TRM), dilumen device (DESD) and others. Primary endpoint: to evaluate the complication rates among these approaches. Secondary curative rate (ESGE criteria).